Skip to main content
Clinical Trials/NCT03657823
NCT03657823
Unknown
Not Applicable

Fetal Growth and Pregnancy Complications Among Women With Heart Disease in Norway: a Cohort Study

Oslo University Hospital1 site in 1 country800 target enrollmentMay 15, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Congenital Heart Disease
Sponsor
Oslo University Hospital
Enrollment
800
Locations
1
Primary Endpoint
Fetal growth
Last Updated
7 years ago

Overview

Brief Summary

An increasing proportion of women with heart disease now go through pregnancy and childbirth. More knowledge about the risk of complications and adverse outcomes for the mother and the baby is needed to guide clinical care in this diverse patient group.

The purpose of this study is to, in a cohort of pregnant women with heart disease;

  • determine fetal growth, and risk of fetal growth restriction and preterm birth
  • determine whether maternal blood biomarkers are associated with development of preeclampsia, the time of delivery and maternal and perinatal adverse outcomes
  • determine the risk of hypertensive pregnancy complications

The expected outcome of the project is to increase the knowledge of optimal diagnosis and treatment of women with heart disease that go through pregnancy to be able to improve clinical care and the outcomes for mother and baby.

Detailed Description

Heart disease is about to become the most important cause of maternal deaths in industrialized countries. In addition, heart disease in pregnancy is associated to an increased rate of fetal growth restriction, premature birth, preeclampsia and other pregnancy complications for the mother and the baby. As many women with congenital or acquired heart disease now go through pregnancy and childbirth, more knowledge about the risk of complications and adverse outcomes for the mother and the baby is needed to guide clinical care in this diverse patient group. The National Unit for Pregnancy and Heart Disease is located at Oslo University Hospital, Rikshospitalet, and receive moderate and high risk pregnant women as referrals from hospitals nationwide for follow-up and treatment. The unit has established Oslo University Hospital Register for Pregnancy and Heart disease; a quality register for maternal and fetal outcome in women with heart disease. The purpose of this study was therefore to, in a cohort of pregnant women with heart disease; * determine fetal growth, and risk of fetal growth restriction and preterm birth * determine whether maternal blood biomarkers are associated with development of preeclampsia, the time of delivery and maternal and perinatal adverse outcomes * determine the risk of hypertensive pregnancy complications By the next two years, 150 patients will be included in two prospective longitudinal studies. In the first study fetal growth and utero-placental-fetal blood flow will be assessed by serial measurements at specific gestational ages. The mother's cardiac function will also be measured. Primary outcome is fetal growth curve and wellbeing at birth. In the second study, biomarkers in maternal serum will be measured during the last half of pregnancy to assess if angiogenetic factors are prognostic for the risk of hypertensive complications. In the last study the researchers will use retrospective data from the Oslo University Hospital Register for Pregnancy and Heart disease to determine the association between heart disease and hypertensive complications in a retrospective cohort of approximately 800 patients. The expected outcome of the project is to increase the knowledge of optimal diagnosis and treatment of women with heart disease that go through pregnancy to be able to improve clinical care and the outcomes for mother and baby.

Registry
clinicaltrials.gov
Start Date
May 15, 2018
End Date
May 31, 2020
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Oslo University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Ingvil Krarup Sørbye

Consultant OBGYN, MD PhD

Oslo University Hospital

Eligibility Criteria

Inclusion Criteria

  • Pregnant women diagnosed with heart disease before or during pregnancy classified as maternal WHO risk class 2-4

Exclusion Criteria

  • Non-consent

Outcomes

Primary Outcomes

Fetal growth

Time Frame: From gestational week 12 until time of birth of baby

Serial measurements of fetal biometry

Occurrence of hypertension/preeclampsia in pregnancy or postpartum

Time Frame: From time of study inclusion until time of discharge from maternity unit after birth of baby

Diagnosis in index pregnancy or postpartum until discharge from maternity unit

Fetoplacental circulation

Time Frame: From gestational week 12 until time of birth of baby

Serial measurements of fetoplacental circulation

Study Sites (1)

Loading locations...

Similar Trials